Endopyelotomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Endopyelotomy is a minimally invasive endoscopic procedure used to treat ureteropelvic junction obstruction (UPJO) — a narrowing at the junction between the renal pelvis (the funnel-shaped reservoir collecting urine from the kidney) and the ureter (the tube conveying urine to the bladder). This obstruction impairs urine drainage from the kidney, leading to hydronephrosis (dilation of the kidney's collecting system), recurrent loin pain (particularly after high fluid intake), urinary tract infections, renal stones, and over time, progressive loss of renal function if untreated.

The procedure involves inserting a telescopic instrument — either a ureteroscope (passed through the urethra, bladder, and up the ureter to the ureteropelvic junction — antegrade or retrograde approach) or a nephroscope (inserted through a percutaneous tract directly into the kidney under fluoroscopic or ultrasound guidance — the percutaneous or antegrade endopyelotomy approach) — to the level of the obstruction. Through this instrument, the narrowed segment of the UPJ is incised — cut full-thickness through the length of the obstructive segment — using an electrocautery cutting device, cold knife, holmium laser, or balloon incision device (Acucise). Following incision, a JJ ureteric stent (also called a double J stent or internal ureteric stent) is placed across the UPJ to maintain the calibre of the incised segment during the healing period, typically left in situ for 4–6 weeks before endoscopic removal.

Endopyelotomy was developed as a minimally invasive alternative to open or laparoscopic pyeloplasty, the traditional surgical repair of UPJO. While pyeloplasty achieves higher long-term success rates (90–95%), endopyelotomy offers a less invasive option with shorter hospitalisation and faster recovery, particularly suitable for select patient populations and cases where the anatomy is favourable.

Endopyelotomy treats ureteropelvic junction obstruction (UPJO), which may be primary (congenital narrowing, usually identified in childhood or early adulthood) or secondary (acquired obstruction from stones, infection, previous surgery, or extrinsic compression by crossing vessels). The primary indication is symptomatic UPJO causing recurrent loin or flank pain, particularly pain provoked by high fluid intake (Dietl's crisis), urinary tract infections, renal calculi forming in the obstructed collecting system, or evidence of progressive hydronephrosis or differential renal function loss on diuretic renography (MAG3 or DTPA nuclear medicine scan).

Endopyelotomy is particularly appropriate for secondary UPJO following previous pyeloplasty or percutaneous stone treatment where scarring has caused recurrent obstruction (secondary endopyelotomy or re-do procedure), as the already-explored anatomy and absence of crossing vessels simplifies the procedure and improves the risk-benefit ratio compared to redo open surgery. Asymptomatic mild hydronephrosis without differential function loss and without symptoms may be managed conservatively with surveillance imaging and renography rather than surgical intervention.

Suitable candidates for endopyelotomy include adults with symptomatic UPJO who have documented obstruction on diuretic renography (T1/2 drainage time above 20 minutes) and no evidence of a large, significantly dilated renal pelvis (AP pelvis diameter above 50 mm is relatively unfavourable for endopyelotomy compared to pyeloplasty), no evidence of a significant crossing lower pole renal vessel (identified on CT angiography), adequate baseline renal function in the affected kidney (differential function above 20% on split renography), and no associated renal stones requiring simultaneous operative management that would be better addressed through percutaneous access anyway.

Endopyelotomy is less successful in the presence of a crossing vessel (lower pole segmental renal artery crossing the UPJ) because the endoscopic incision cannot address the extrinsic vascular compression and carries a risk of vessel damage causing significant haemorrhage. In these cases, laparoscopic or robotic-assisted dismembered pyeloplasty — which can simultaneously transpose the crossing vessel — is strongly preferred. Patients who are anticoagulated require bridging or reversal before the procedure. Patients with active urinary tract infection require antibiotic treatment to sterility before proceeding.

Three principal endoscopic techniques are used for endopyelotomy. Retrograde endopyelotomy (ureteroscopic endopyelotomy) uses a flexible or semi-rigid ureteroscope passed cystoscopically up the ureter to the UPJ under fluoroscopic guidance, with the incision performed under direct vision using a holmium:YAG laser or electrocautery. This approach avoids percutaneous puncture into the kidney, carries no nephrostomy tube requirement, and is suitable for patients with a renal pelvis that is not grossly dilated. It is technically demanding due to working through a long, narrow flexible ureteroscope.

Antegrade percutaneous endopyelotomy accesses the UPJ from above — a percutaneous nephrostomy tract is established under fluoroscopic and ultrasound guidance under general anaesthesia, dilated to allow passage of a nephroscope, and the incision is made under direct vision at the UPJ from the renal pelvis side. This approach is favoured when the renal pelvis is grossly dilated (providing ample working space) or when simultaneous stone extraction is needed. The Acucise balloon catheter endopyelotomy involves fluoroscopic guidance alone without direct vision: a cutting wire mounted on a balloon is positioned at the UPJ under fluoroscopy, and electrical current is passed through the wire as the balloon is inflated, incising the UPJ segment. This 'blind' technique carries a higher risk of incomplete incision and vascular injury than direct-vision methods and has largely been replaced by laser or electrocautery techniques.

Endopyelotomy achieves successful relief of UPJO obstruction in 70–85% of appropriately selected patients at 1–2 years, compared to 90–95% success rates for dismembered laparoscopic or open pyeloplasty. This difference in success rates explains why pyeloplasty remains the gold standard, particularly for primary UPJO in young patients who benefit from durable long-term results. However, the minimally invasive nature of endopyelotomy offers significant practical advantages: hospitalisation of 1–2 days versus 3–5 days for laparoscopic pyeloplasty, faster return to normal activities (2–4 weeks versus 4–6 weeks), absence of abdominal incisions with their associated risk of hernia and wound complications, and the option to convert to pyeloplasty if endopyelotomy fails without having compromised the anatomical planes.

For secondary UPJO (post-surgical obstruction), endopyelotomy success rates approach those of primary cases or are higher in some series, because the absence of crossing vessels and the prior surgical dissection simplifies the procedure. Patient satisfaction with symptom relief after successful endopyelotomy is high — loin pain resolves in over 90% of patients with a successful procedural outcome, and UTI rates decrease significantly with resolution of stasis.

Endopyelotomy carries specific risks inherent to both the endoscopic approach and the proximity of vascular structures at the UPJ. The most serious complication is haemorrhage from injury to a crossing renal vessel or branch of the renal artery, which can be life-threatening and require emergency angiographic embolization or conversion to open surgery. The reported rate of significant haemorrhage is approximately 1–3%, higher in the presence of crossing vessels (hence their assessment by preoperative CT angiography). Urosepsis — systemic infection from bacteraemia during instrumentation of an obstructed collecting system — requires prophylactic antibiotics perioperatively and sterile urine before the procedure.

The internal JJ ureteric stent placed after endopyelotomy causes lower urinary tract symptoms (urinary frequency, urgency, dysuria, haematuria) in the majority of patients, resolving after stent removal at 4–6 weeks. Stent migration, encrustation (calcification on the stent if left in situ too long), or forgotten stents (a clinical and medicolegal risk) are well-recognised stent complications that require systematic tracking of all stent insertions with dates and planned removal. Stricture recurrence at the incised UPJ after endopyelotomy occurs in 15–30% of cases at 5 years, compared to 5–10% for pyeloplasty. Recurrent symptoms warrant repeat diuretic renography and consideration of redo endopyelotomy or conversion to pyeloplasty.

Following endopyelotomy, the internal JJ ureteric stent remains in situ for 4–6 weeks to hold the incised UPJ open during the healing period. Stent removal is performed endoscopically (flexible cystoscopy under local anaesthesia) in the outpatient setting at 4–6 weeks. Patients are counselled that stent-related symptoms (urgency, frequency, occasional haematuria) are expected and should resolve after removal. Moderate activity restriction and avoidance of vigorous exercise is recommended while the stent is in situ to reduce haematuria and stent displacement risk.

Functional follow-up with diuretic renography (MAG3 scan) and renal ultrasound is performed at 3 months after stent removal to assess whether the incision has healed with an adequately patent UPJ. Deterioration in drainage parameters on renography, worsening hydronephrosis on ultrasound, or recurrence of loin pain indicates failure and warrants referral to a urological surgeon for consideration of laparoscopic pyeloplasty. Annual surveillance ultrasound is performed for 3–5 years after successful endopyelotomy to monitor for late recurrence of hydronephrosis.

Endopyelotomy is less expensive than laparoscopic pyeloplasty due to shorter operative time, lower complication rates, shorter hospitalisation, and absence of laparoscopic port and tissue handling equipment costs. In the US, endopyelotomy in a hospital setting costs USD 8,000–18,000 inclusive of surgeon fees, anaesthesia, hospital charges, and stent removal — compared to USD 15,000–30,000 for laparoscopic pyeloplasty. These costs are generally covered by health insurance for documented symptomatic UPJO with functional impairment.

For patients seeking urology treatment internationally, India offers both endopyelotomy and laparoscopic pyeloplasty at 70–80% cost savings versus US prices. Endopyelotomy at a specialist urology centre in India (Delhi, Mumbai, Chennai, Hyderabad) costs approximately USD 1,500–3,000 including hospitalisation, anaesthesia, and stent removal. Laparoscopic pyeloplasty costs USD 2,500–5,000 in India. Thailand (Bumrungrad International, Bangkok) and Turkey offer costs of USD 3,000–6,000. Patients should verify the treating urologist's subspecialty expertise in endourology and stone disease, as these procedures require experience with flexible ureteroscopy and percutaneous renal access.

The most established alternative to endopyelotomy for UPJO is laparoscopic (or robotic-assisted) dismembered pyeloplasty — the Anderson-Hynes procedure — in which the narrowed UPJ is excised and the renal pelvis and ureter are reanastomosed over a stent in a tension-free, dependent position. This procedure carries a 90–95% long-term success rate and is the preferred treatment for primary UPJO in adults and children, particularly when crossing vessels are present (which can be transposed simultaneously) or when the renal pelvis is severely dilated (above 50 mm). Robotic-assisted pyeloplasty achieves equivalent outcomes to laparoscopic pyeloplasty with the ergonomic advantages of robotic instrumentation.

For patients managed conservatively — asymptomatic UPJO with mild hydronephrosis and preserved differential function — watchful waiting with 6–12-monthly diuretic renography and ultrasound is appropriate, proceeding to surgery only if function deteriorates, symptoms develop, or recurrent UTIs or stones occur. Open pyeloplasty is rarely performed in the modern era but remains a valid alternative when laparoscopic or robotic approaches are not available, particularly in low-resource settings. Balloon dilation of the UPJ (endopyeloplasty) is a historical approach with lower success rates than endopyelotomy and is not currently recommended.